Nothing Special   »   [go: up one dir, main page]

ATE286122T1 - Protein c derivate - Google Patents

Protein c derivate

Info

Publication number
ATE286122T1
ATE286122T1 AT01904786T AT01904786T ATE286122T1 AT E286122 T1 ATE286122 T1 AT E286122T1 AT 01904786 T AT01904786 T AT 01904786T AT 01904786 T AT01904786 T AT 01904786T AT E286122 T1 ATE286122 T1 AT E286122T1
Authority
AT
Austria
Prior art keywords
derivatives
wild
protein
human protein
type
Prior art date
Application number
AT01904786T
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE286122T1 publication Critical patent/ATE286122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AT01904786T 2000-02-02 2001-01-19 Protein c derivate ATE286122T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17980100P 2000-02-02 2000-02-02
US18919700P 2000-03-14 2000-03-14
PCT/US2001/000020 WO2001057193A2 (en) 2000-02-02 2001-01-19 Protein c derivatives

Publications (1)

Publication Number Publication Date
ATE286122T1 true ATE286122T1 (de) 2005-01-15

Family

ID=26875697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01904786T ATE286122T1 (de) 2000-02-02 2001-01-19 Protein c derivate

Country Status (9)

Country Link
US (1) US6841371B2 (de)
EP (1) EP1255821B1 (de)
JP (1) JP2003521919A (de)
AT (1) ATE286122T1 (de)
AU (1) AU2001232736A1 (de)
CA (1) CA2399267A1 (de)
DE (1) DE60108076T2 (de)
ES (1) ES2234807T3 (de)
WO (1) WO2001057193A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399267A1 (en) 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
JP2003521938A (ja) 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP2005518801A (ja) * 2002-03-01 2005-06-30 テイ・エイ・シー・スロムボシス・アンド・コアグラシヨン・アクテイエボラーク 組換えプロテインｃバリアント
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
CA2574598A1 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
EP1896059B1 (de) * 2005-06-24 2012-12-19 Drugrecure ApS Atemwegs-administration eines gewebefaktorweghemmers bei entzündungskrankheiten, die den atemtrakt betreffen
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296413A2 (de) 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrides Protein C und Verfahren zur Herstellung
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5196322A (en) 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
JP2774154B2 (ja) * 1989-08-10 1998-07-09 帝人株式会社 活性化ヒトプロテインｃ誘導体
US5358932A (en) 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
DK0506821T3 (da) * 1989-12-29 1998-03-30 Zymogenetics Inc Hybridt protein C
IL97311A0 (en) 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5270178A (en) 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
US5847085A (en) 1996-11-08 1998-12-08 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
SE9701228D0 (sv) * 1997-04-03 1997-04-03 Bjoern Dahlbaeck Rekombinanta protein-C-och protein-S-varianter
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP2002542832A (ja) * 1999-04-30 2002-12-17 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
EP1237917A2 (de) * 1999-11-19 2002-09-11 Eli Lilly And Company Derivate aus protein c
CA2399267A1 (en) 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
JP2003521938A (ja) 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
DE60111620T2 (de) 2000-03-28 2006-05-18 Eli Lilly And Co., Indianapolis Aktiviertes protein c zur behandlung von pankreatitis
EP1370649A1 (de) 2001-03-02 2003-12-17 T.A.C. Thrombosis and Coagulation AB Varianten von protein c

Also Published As

Publication number Publication date
US20030207435A1 (en) 2003-11-06
DE60108076D1 (de) 2005-02-03
JP2003521919A (ja) 2003-07-22
EP1255821B1 (de) 2004-12-29
EP1255821A2 (de) 2002-11-13
WO2001057193A3 (en) 2002-02-07
WO2001057193A2 (en) 2001-08-09
US6841371B2 (en) 2005-01-11
AU2001232736A1 (en) 2001-08-14
ES2234807T3 (es) 2005-07-01
CA2399267A1 (en) 2001-08-09
DE60108076T2 (de) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
DK0690720T3 (da) Terapeutiske anvendelser af baktericide/permeabilitetsforøgende proteinprodukter
DE60034155D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
DE69831566D1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
PT1196444E (pt) Conjugados de exendina-4 e seus usos medicos
SE9800836D0 (sv) New Compounds
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DE60108076D1 (de) Protein c derivate
ATE353366T1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE60331665D1 (de) Nicht-neutralisierende anti-apc-antikörper
HUP0102444A2 (hu) Protein-C származékok
WO2001036462A3 (en) Protein c derivatives
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
ATE291586T1 (de) Humanes antibiotisches protein
EP1409710A4 (de) Nukleinsäure und dieser entsprechendes, 161p5c5 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
Xue et al. Activated protein C stimulates expression of angiogenic factors in human skin cells, angiogenesis in the chick embryo and cutaneous wound healing in rodents
JP2003286300A5 (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties